Alzeca Biosciences Company
Alzeca Biosciences develops novel advanced imaging agents for the early diagnosis of neurodegenerative diseases, including Alzheimer’s Disease. Alzheimer’s affects approximately 5.5M Americans at a cost of over $226 billion in care, and affects over 27 million patients worldwide. Its incidence is projected to quadruple by 2050 with costs exceeding $1 trillion in the US alone, unless a more effective diagnostic and treatment method is achieved.
Founded Date:
2012-01-01
Last Funding Date:
2019-10-31
Industry:
Electrometry
Total Funding:
11000000
Headquarters:
Houston,Texas,United States,North America
Funding Status:
private
Super Industry:
Quantum Sensing
Funding Stage:
Early Stage Venture
Funding Total Value:
11000000
Founders:
Jason Eriksen